**[LMN Template for Whole Genome Sequencing]**

Patient: \*\*\*

Insurance Company: \*\*\*

Subscriber Name: \*\*\*

Policy #:\*\*\*

Reference Number: \*\*\*

Dear Claims Specialist,

I am writing this letter of medical necessity on behalf of my patient [Patient Name] to request coverage for Whole Genome Sequencing (also known as WGS) to be performed at [Lab Name], a high complexity CLIA-certified, laboratory located in [Lab Location].

The purpose of this test is to rapidly identify the underlying molecular basis of a genetic disorder in an affected individual by performing a comprehensive analysis of the patient's entire genome to enable real time changes in clinical management. This test has the potential to change management, improve clinical outcomes and reduce cost of total care for this patient.

1. This case has been evaluated by [ordering provider(s)], who believes there is a high likelihood of a genetic etiology.
   1. At the present time we cannot recognize a specific clinical diagnosis. Due to the heterogeneous nature of rare genetic disorders, the most efficient and cost-effective way to confirm a genetic diagnosis in this patient is to perform whole genome sequencing as recommended by the American College of Medical Genetics and Genomics.
   2. Rather than sequencing the many potential candidate individual genes, WGS is the fastest (*Petrikin* et.al.) and most cost-effective way (*Farnaes* et. al) to search for a mutation among the large number of potential genes that could be causing this condition.
2. The [patient/family] has been counseled about the potential risks of genetic testing by a certified genetic counselor who will also provide the results to the family. [remove if inapplicable]
3. There is potential for a change in management and clinical outcome for this case. In this case, specific changes that may be anticipated include: \*\*\*

Without a specific genetic etiology, this individual is at risk for \*\*\*

Due to these benefits, and consistent with specialty guidelines, genome sequencing is medically warranted in my patient. As such, I am recommending this medically necessary test and affirm that my patient has provided informed consent for genetic testing.

Comparing this individual's sequence to additional family member's data will significantly increase the utility of the test results and increase the likelihood of identifying a disease-causing gene while decreasing the chance of obtaining variants of unknown clinical significance (*Clark, 2018*). This method of evaluation is especially important for individuals with apparently sporadic disease, when no one else in the family is similarly affected. By analyzing parents and unaffected siblings in cases of sporadic disease, it is frequently possible to identify de novo or new mutations in the patient not present in either parent or to identify recessive diseases with one mutation inherited from each parent .Therefore, we are requesting “trio” testing of the affected patient and both biological parents. [remove if inapplicable]

The clinical applications of Whole Genome Sequencing (WGS) have now been well supported by the following lines of evidence:

1. **The Policy Statement by The American College of Medical Genetics and Genomics** published in 2012 on the clinical application of genomic sequencing recommends genome sequencing in four clinical scenarios (ACMG Board). Most relevant to our patient:

*“WGS should be considered in the clinical diagnostic assessment of a phenotypically affected individual when: A patient presents with a defined genetic disorder that demonstrates a high degree of genetic heterogeneity, making WGS analysis of multiple genes simultaneously a more practical approach.”*

1. **The clinical utility of WGS has been well established** and therefore should not be considered experimental.

* WGS has the advantage of speed and efficiency relative to WES and Sanger sequencing of multiple genes. WGS has greater ability to detect large deletions or duplications in protein-coding regions compared to WES and is superior to chromosome microarray testing in detecting copy number variants in the chromosomes.
* WES shares some limitations with Sanger sequencing, for example, it will not identify the mutations in intronic sequences or gene regulatory regions; chromosomal changes; large deletions; duplications or rearrangements within genes or nucleotide repeats.
* Whole genome sequencing in a randomized control trial has demonstrated increased diagnostic yield and reduced time to diagnosis compared with standard care that includes panel and whole exome testing (*Petrikin*).
* Whole genome sequencing has been shown to have a superior diagnostic utility to chromosome microarray. Among studies published in 2017, the diagnostic utility of WGS was significantly greater than CMA (P < 0.0001, I2 = 13% and I2 = 40%, respectively). The clinical utility of WGS (0.27, 95% CI 0.17–0.40, I2 = 54%) has been shown on meta-analysis to be superior to WES (0.17, 95% CI 0.12–0.24, I2 = 76%) and higher than CMA (0.06, 95% CI 0.05–0.07, I2 = 42%) (*Clark*).
* A systematic review of diagnostic yield of genetic testing among patients with epilepsy performed in 2022 determined that WGS had a 48% yield in this population (compared to 24% yield with WES, 19% for multi-gene panels, and 9% with CMA) (*Sheidley*).
* A 2023 National Society of Genetic Counselors (NSGC) workgroup established robust practice guidelines for genetic testing in epilepsy, recommending multi-gene panel testing or exome/genome sequencing as first tier testing for all individuals with unexplained epilepsy, based on yield of testing, ‘as well as the clinical utility of genetic testing to guide treatment/medical management, revise, or establish prognosis and/or provide reproductive risk counseling’ (*Smith).*
* Rapid whole genome sequencing in neonates has demonstrated both improved clinical outcomes and a reduction in the total cost of care (*Farnaes*) compared with standard workup [remove if inapplicable]

**We request your review of the following testing for preauthorization:**

Test Requested:  \*\*\*

Test Code: \*\*\*

Lab Name: \*\*\*

Lab Phone: \*\*\*

CPT codes: \*\*\*

**ICD10 Codes:** \*\*\*

The blood draw would be completed at [Lab/Hospital] for the family’s convenience. Billing would be coordinated by [Billing Institution/Provider]. Ordering provider would be [Ordering Provider].

Thank you for your review and consideration. I hope you will support this request for genetic testing coverage for [Patient Name]. If you have questions, or if I can be of further assistance, please do not hesitate to contact me at [Clinician Contact Info].

Sincerely,

\*\*\*

**References**

Smith, L., Malinowski, J., Ceulemans, S., Peck, K., Walton, N., Sheidley, B. R., & Lippa, N. (2023**). Genetic testing and counseling for the unexplained epilepsies: An evidence-based practice guideline of the National Society of Genetic Counselors.** *Journal of Genetic Counseling*, 32, 266–280.

Sheidley BR, Malinowski J, Bergner AL, Bier L, Gloss DS, Mu W, et al. **Genetic testing for the epilepsies: A systematic review.** *Epilepsia*. 2022; 63: 375–387.

Petrikin JE, Cakici JA, Clark MM, Willig LK, Sweeney NM, Farrow EG, Saunders CJ, Thiffault I, Miller NA, Zellmer L, Herd SM, Holmes AM, Batalov S, Veeraraghavan N, Smith LD, Dimmock DP, Leeder JS, Kingsmore SF **The NSIGHT1randomized controlled trial: rapid whole-genome sequencing for accelerated etiological diagnosis in critically ill infants** NPJ Genom Med. 2018 Feb 9;3:6. doi: 10.1038/s41525-018-0045-8. eCollection 2018. PMID: 29449963

Farnaes L, Hildreth A, Sweeney NM, Clark MM, Chowdhury S, Nahas S, Cakici JA, Benson W, Kaplan RH, Kronick R, Bainbridge MN, Friedman J, Gold JJ, Ding Y, Veeraraghavan N, Dimmock D, Kingsmore SF. **Rapid Whole Genome Sequencing Decreases Morbidity and Healthcare Cost of Hospitalized Infants**. NPJ Genom Med. 2018 Apr 4;3:10. doi: 10.1038/s41525-018-0049-4. eCollection 2018. PMID: 29644095

Clark MM, Stark Z, Farnaes L, Tan TY, White SM, Dimmock D, Kingsmore SF. **Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases.** NPJ Genomic Medicine volume 3, Article number: 16 (2018) doi: 10.1038/s41525-018-0053-8

ACMG Board of Directors. **ACMG Policy Statement: Points to consider in the clinical application of genomic sequencing.** Genet Med. 2012;14(8):759-76.